Phase II Study of Thalidomide in Mastocytosis
- Determine the objective response rate at 6 months in patients with systemic
mastocytosis treated with thalidomide.
- Determine the tolerability of this drug in these patients.
OUTLINE: This is a multicenter study.
Patients receive oral thalidomide once daily for 6 months in the absence of disease
Allocation: Non-Randomized, Primary Purpose: Treatment
Objective reduction of the infiltration rate at 6 months
Centre Hospitalier Universitaire d'Amiens
United States: Federal Government